Lineage Cell Therapeutics Extends Cash Runway to Q3 2028 After Q2 Earnings
Lineage reports $50.8 million in cash, extending runway while advancing OpRegen and OPC1 clinical programs with milestone potential. Lineage Cell Therapeutics (LCTX) ended Q2 with $50.8 million in cash and marketable securities, projecting a runway into Q3 2028. Revenue de